SQI Diagnostics Appoints New Member to Board of Directors



    TORONTO, Nov. 12 /CNW/ - SQI Diagnostics Inc. (TSX-Venture: SQD), a
medical systems automation company focused on evolving laboratory-based
biomarker testing, today announced that Peter Winkley has been appointed to
its Board of Directors and will join the Company's Audit Committee.
    "We are pleased to welcome Peter to our Board of Directors. His extensive
finance experience and his understanding of the critical aspects of the
commercial laboratory diagnostics business at MDS Inc. will make him a key
addition to our Board as we move into a pivotal phase of our development with
the commercialization of our automated biomarker testing platform," said
Eric Schneider, Chairman of SQI Diagnostics' Board of Directors. "Peter's
12 years of experience as a chartered accountant with Ernst & Young will be
invaluable in his role as a member of our Audit Committee."
    Peter Winkley is currently the Vice-President, Corporate Finance and
Treasurer at MDS Inc. Until February 2007, when the business was sold, MDS was
the largest operator of clinical laboratories in Canada. At MDS, he is
responsible for corporate financial issues including all external financial
reporting and treasury activities. Mr. Winkley has also been responsible for
corporate planning and reporting to executive management and the Board of
Directors, and is involved in all areas of the business, including the
laboratory diagnostics business. Prior to joining MDS Inc. in 1995,
Mr. Winkley was a Senior Manager at Ernst & Young where he conducted, managed
and directed audits of public and private companies. He is a Chartered
Accountant and holds a Bachelor of Commerce degree from the University of
Toronto.

    About SQI Diagnostics

    SQI Diagnostics is a medical systems automation company focused on
evolving laboratory-based biomarker testing. Using automation and proprietary
miniaturization technologies, SQI Diagnostics significantly improves the
economies of scale for laboratories performing multiple biomarker testing at
high volumes, allowing them to deliver patient results faster using less labor
and fewer resources. SQI Diagnostics' initial products target the $1.4 billion
autoimmune disease market, with initial products for Rheumatoid Arthritis and
Thrombosis scheduled for launch in 2007. SQI Diagnostics is based in Toronto,
Canada. For further information please visit www.sqidiagnostics.com.

    Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking
statements.

    This release was prepared by management of the Company who takes full
    responsibility for its contents. The TSX Venture Exchange has not
    reviewed and does not accept responsibility for the adequacy or accuracy
    of this news release.

    %SEDAR: 00021000E




For further information:

For further information: Chief Financial Officer, Andrew Morris, (416)
674-9500 ext. 229, amorris@sqidiagnostics.com; Investor Relations, James
Smith, (416) 815-0700 ext. 229, jsmith@equicomgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890